Lisata Therapeutics Inc Stock Price, News & Analysis

Lisata Therapeutics (Nasdaq: LSTA) and Catalent announced on October 8, 2025 a global, non-exclusive license allowing Catalent to incorporate Lisata’s certepetide and analogs into ADCs developed with Catalent’s SMARTag® platform.

Catalent gains worldwide rights to evaluate certepetide as SMARTag® payloads across multiple ADCs and may partner third parties. Lisata is eligible for over $10 million in tiered study-initiation milestone payments plus revenue sharing on future sales and partnerships. Catalent’s preclinical data provide proof-of-concept that iRGD peptides can improve ADC efficacy and pharmacokinetics; related preclinical work will be highlighted at the November World ADC conference in San Diego.

Lisata Therapeutics (Nasdaq: LSTA) reported encouraging preliminary results from the pancreatic cancer (PDAC) cohort of its Phase 1/2a CENDIFOX trial, evaluating certepetide in combination with FOLFIRINOX-based therapies. The trial, led by Dr. Anup Kasi at KU Cancer Center, showed promising outcomes in treating resectable and borderline resectable PDAC.

Key findings from the 35-patient PDAC cohort include: 50% R0 resection rate and 70% pathologic partial response among the 10 patients who completed pre-surgical therapy. The study demonstrated a 60% two-year overall survival rate and 12-month median disease-free survival. Importantly, the combination therapy showed enhanced immune cell infiltration and increased expression of immune markers, suggesting potential transformation of pancreatic tumors from "immune-cold" to "immune-hot."

Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and serious diseases, announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference.

The company's President and CEO, David J. Mazzo, Ph.D., will deliver a pre-recorded corporate overview presentation, which will be available on-demand starting September 5, 2025, at 7:00 a.m. ET. The conference is scheduled to take place in New York City from September 8-10, 2025.

Lisata Therapeutics (NASDAQ:LSTA) reported Q2 2025 financial results and provided updates on its clinical development portfolio. The company's lead candidate certepetide showed positive preliminary results in multiple clinical trials for advanced solid tumors. Key financial metrics include $22.0 million in cash and equivalents, with runway extending into Q4 2026.

Notable developments include positive preliminary data from the ASCEND trial for pancreatic cancer and the iLSTA trial. The company reported Q2 2025 revenue of $70,000 and reduced operating expenses to $4.9 million, down 10.6% year-over-year. A new USPTO patent extends certepetide's protection until March 2040.

Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company focused on developing therapies for advanced solid tumors and serious diseases, will release its Q2 2025 financial results on Thursday, August 7, 2025, after market close.

The company will host a conference call at 4:30 p.m. Eastern time. Participants must pre-register to receive dial-in details and are encouraged to join 15 minutes before the start time. A live webcast will be available on Lisata's website, with a 12-month replay option.

Lisata Therapeutics (Nasdaq: LSTA) announced the completion of patient enrollment in their Phase 1b/2a iLSTA trial, evaluating certepetide in combination with standard-of-care chemotherapy and immunotherapy for locally advanced non-resectable pancreatic ductal adenocarcinoma (PDAC).

The trial's preliminary data, presented at ESMO-GI 2025, showed remarkable results: an overall response rate of 60% and a disease control rate of 100%. Of the 20 participants, 13 showed partial response, 1 exhibited complete response, and 6 demonstrated stable disease. Additionally, 16 out of 20 participants experienced decreased CA19-9 levels, with 7 showing >90% reduction.

The study, conducted at St John of God Subiaco Hospital in Australia, divided participants into three cohorts, with the largest group (Cohort 3, n=20) receiving the full combination therapy of chemotherapy, durvalumab, and certepetide.

Lisata Therapeutics (Nasdaq: LSTA) has secured a new composition of matter patent for certepetide from the USPTO, extending protection until March 2040 with potential for further extension. The patent (U.S. Patent No. 12,351,653) covers certepetide's chemical structure, pharmacokinetic properties, manufacturing methods, and applications for treating solid tumor cancers.

This strategic development provides Lisata with the strongest form of IP protection, preventing others from manufacturing or selling the drug. CEO David J. Mazzo emphasized that this patent milestone enhances certepetide's commercial value by delaying generic competition and strengthens the company's position in potential partnership negotiations.

Lisata Therapeutics (NASDAQ:LSTA) announced positive preliminary results from Cohort B of the ASCEND Phase 2b trial evaluating certepetide in metastatic pancreatic cancer. The trial, conducted across 24 sites in Australia and New Zealand, demonstrated significant improvements in patient outcomes.

Key findings include progression-free survival of 60.8% vs 25% (certepetide vs placebo), median progression-free survival of 7.5 vs 4.7 months, and objective response rate of 45.2% vs 19%. Median overall survival improved to 10.32 months vs 9.23 months. The Cohort B regimen, which added a second dose of certepetide, showed meaningful improvements compared to Cohort A's single-dose approach.

Final data from both cohorts is expected later this year, with results suggesting certepetide could potentially transform treatment for metastatic pancreatic cancer, which currently has a five-year survival rate of just 13%.

Lisata Therapeutics (NASDAQ: LSTA) and GATC Health Corp. have expanded their strategic alliance to enhance drug discovery and development using AI technology. The partnership combines Lisata's drug development expertise with GATC's Multiomics Advanced Technology (MAT) platform. A key focus is advancing GATC's AI-discovered therapeutic for opioid use disorder (OUD) into Phase 1 human trials in early 2026. The MAT platform, validated by UC Irvine with 86% sensitivity and 91% specificity, will help identify new combination therapies and predict safety and efficacy. GATC will cover R&D costs while Lisata receives milestone fees and royalties from commercialized products. The collaboration aims to accelerate drug development, potentially reducing discovery time from 5-6 years to one year and creating up to $400 billion in value for the pharmaceutical industry by end-2025.